Oculis’ strategy is to leverage its SNP technology platform to develop transformative eye drop ophtalmique solutions that have improved properties over approved drugs and address large unmet medical needs to bring potentially better efficacy, safety and convenience to both patients and physicians.
Oculis’ most advanced product candidate is dexamethasone soluble nanoparticle eye drops, OC-118 which is being developed in diabetic macular edema (DME). OC-118 has also been tested in a front of the eye in a pilot clinical trial and showed a promising profile.
Oculis pipeline also includes three candidates in pre-clinical stages for potential development in glaucoma, dry eye and neo-vascular retino-pathies.
For further information, contact us at firstname.lastname@example.org